Stock Events

Stock Events

Cullinan Therapeutics 

$13.86
13
-$0.55-3.82% Today

Statistics

Day High
14.41
Day Low
13.86
52W High
-
52W Low
-
Volume
333
Avg. Volume
-
Mkt Cap
818.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.95
-0.89
-0.83
-0.77
Expected EPS
-0.832704
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-334.77MNet Income

Analyst Ratings

$32.80Average Price Target
The highest estimate is 38.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGEM.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma, acquired by Pfizer, focuses on targeted small molecule drugs for cancer, competing in oncology.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals works on cellular metabolism to develop treatments for cancer, making it a competitor in the oncology field.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation offers a range of products for oncology, directly competing with Cullinan in the cancer treatment market.
Exelixis
EXEL
Mkt Cap10.41B
Exelixis, Inc. is focused on developing and commercializing new medicines for the treatment of cancer, competing in the oncology sector.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a significant portfolio in oncology, competing on a global scale in cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a broad range of cancer therapies, making it a major competitor in the oncology market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including oncology, competing with Cullinan Oncology in developing cancer treatments.

About

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Show more...
CEO
ISIN
US2300311063

Listings

XNAS
US
CGEM
BOATS
BOATS
CGEM.BOATS

0 Comments

Share your thoughts

FAQ

What is Cullinan Therapeutics stock price today?▼
The current price of CGEM.BOATS is $13.86 USD — it has decreased by -3.82% in the past 24 hours. Watch Cullinan Therapeutics stock price performance more closely on the chart.
What is Cullinan Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cullinan Therapeutics stocks are traded under the ticker CGEM.BOATS.
What is Cullinan Therapeutics market cap?▼
Today Cullinan Therapeutics has the market capitalization of 818.79M
When is the next Cullinan Therapeutics earnings date?▼
Cullinan Therapeutics is going to release the next earnings report on May 07, 2026.
What were Cullinan Therapeutics earnings last quarter?▼
CGEM.BOATS earnings for the last quarter are -0.77 USD per share, whereas the estimation was -0.81 USD resulting in a +4.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cullinan Therapeutics revenue for the last year?▼
Cullinan Therapeutics revenue for the last year amounts to 0 USD.
What is Cullinan Therapeutics net income for the last year?▼
CGEM.BOATS net income for the last year is -334.77M USD.
When did Cullinan Therapeutics complete a stock split?▼
Cullinan Therapeutics has not had any recent stock splits.